Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | HCK | P08631 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12984983 | 0.82 | IRAK4 (0.38) | MKNK2NTRK1CCNA2CDK2CCNA1 | |
| SCHEMBL12984978 | 0.82 | IRAK4 (0.38) | MKNK2NTRK1CCNA2CDK2CCNA1 | |
| SCHEMBL23228217 | 0.79 | MKNK2 (0.36) | MKNK2NTRK1MKNK1PI4KBEGFR | |
| SCHEMBL27934660 | 0.78 | MKNK2 (0.35) | MKNK2NTRK1MKNK1IRAK4 | |
| SCHEMBL18238495 | 0.77 | NTRK1 (0.41) | NTRK1 | |
| SCHEMBL28061207 | 0.75 | MKNK2 (0.40) | MKNK2MKNK1PI4KBEGFRPIK3CD | |
| SCHEMBL256370 | 0.75 | MKNK2 (0.45) | MKNK2MKNK1EGFRPIK3CB | |
| SCHEMBL30694603 | 0.75 | MKNK2 (0.45) | MKNK2MKNK1EGFRPIK3CB | |
| SCHEMBL16884033 | 0.74 | PDE10A (0.31) | CDK2 | |
| SCHEMBL18926936 | 0.74 | MKNK2 (0.39) | MKNK2DYRK1AMKNK1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230339916-A1 | PLANT GROWTH REGULATOR COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2023-10-26 | — | — | US | disclosed |
| US-20230339916-A1 | PLANT GROWTH REGULATOR COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2023-10-26 | — | — | US | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-09-07 | — | — | US | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| EP-3934757-B1 | 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | INST OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR V V I (CZ) | 2023-02-22 | — | — | EP | disclosed |
| WO-2022272060-A1 | EP2 ANTAGONIST COMPOUNDS | RESERVOIR NEUROSCIENCE, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-8759510-B2 | Nucleoside cyclicphosphates | GILEAD PHARMASSET LLC (US) | 2014-06-24 | — | — | US | disclosed |
| CN-103347866-A | Novel compound as respiratory stimulants for treatment of breathing control disorder or disease | GALLEON PHARMACEUTICALS INC | 2013-10-09 | — | — | CN | disclosed |
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | GILEAD PHARMASSET LLC (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | GILEAD PHARMASSET LLC (US) | 2012-10-11 | — | — | US | disclosed |
| US-8173621-B2 | Nucleoside cyclicphosphates | GILEAD PHARMASSET LLC (US) | 2012-05-08 | — | — | US | disclosed |
| US-7842672-B2 | Phosphonate inhibitors of HCV | GILEAD SCIENCES, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20080107628-A1 | Polymerase inhibitors | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
| CN-1134439-C | Pyrrolo [2,3D ] pyrimidines and their use as tyrosine kinase inhibitors | 艾博特股份有限两合公司 | 2004-01-14 | — | — | CN | disclosed |
| CN-1259950-A | Pyrrolo [2,3D] pyrimidines and their use as tyrosine kinase inhibitors | BASF AG (DE) | 2000-07-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | MKNK2 2939/4885NTRK1 2548/4885CCNA2 4755/4885 |
| US-20080107628-A1 | Polymerase inhibitors | POLR2H, POLR2E, POLR1E | MKNK2 2939/4885NTRK1 4763/4885CCNA2 744/4885 |
| US-20230339916-A1 | PLANT GROWTH REGULATOR COMPOUNDS | MYB, TOE1, SUB1 | MKNK2 2080/4885NTRK1 3205/4885CCNA2 69/4885 |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | MKNK2 3105/4885NTRK1 3855/4885CCNA2 1786/4885 |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | CARM1, TIAM1, ADRM1 | MKNK2 3066/4885NTRK1 3870/4885CCNA2 1771/4885 |
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | MKNK2 3557/4885NTRK1 4637/4885CCNA2 1647/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | MKNK2 2939/4885NTRK1 2548/4885CCNA2 4755/4885 |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | MKNK2 929/4885NTRK1 4190/4885CCNA2 1280/4885 |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | MKNK2 3557/4885NTRK1 4637/4885CCNA2 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.